Cáncer de mama: subtipos e innovación inmunoterapéutica para el triple negativo

Destacados Scmihd P, Adams S, Rugo H S, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018. Pfefferle A. D., Agrawal Y. N., Koboldt D. C., et al . Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech. 2016;  9: 749-757. Breast cancer org. [Internet ] Estado del HER2 (2016 Sep 29). Disponible en:  https://www.breastcancer.org/es/sintomas/diagnostico/her2 Mark M. Moasser. The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis. [Internet] 2007 Apr 30 [consultado 25 Oct 2018] ; 26(45): 6469-6487. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021475/ M. Arroyo Yustos*, M. Martín Angulo, M. Álvarez-Mon Soto. Cáncer de mama. Medicine [Internet].2017 [concultado 25 Oct 2018]; 12(34):2011-23. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: Ameri...